This stable and consistent difference in hepatic and serum S100A9 expression among different phenotypes of NAFLD demonstrates its potential to be used as a biomarker to monitor NAFLD progression. Here, S100A9 is linked to metabolic dysfunction-associated steatotic liver disease.